KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
GAITHERSBURG, Md., Feb. 11, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 25, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2015, recent business developments, financial outlook for full year 2016, and revenue guidance for the first quarter of 2016.
This conference call can be accessed live by telephone or through Emergent’s website:
| Live Teleconference Information: Dial in number: (855) 766-6521 International dial in: (262) 912-6157 Passcode: 46021005 | Live Webcast Information: Visit emergentbiosolutions.com and select the “Investors” section |
Pre-registering for the live call will expedite access and minimize hold times. You will be issued a passcode to bypass the operator and connect directly. To pre-register for the call, visit the following website: edge.media-server.com/m/p/9j5eeynk.
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions Inc.
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com.
Follow us on twitter: @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Vice President, Global Public Affairs and Corporate Responsibility 240-631-3394 [email protected]
